Famciclovir
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Famciclovir: From Herpes Zoster to Post-Infectious Neuralgia
One-Sentence Summary
Famciclovir is a well-established oral antiviral, originally used for herpes zoster (shingles) and related herpesvirus infections — though the evidence pack itself does not carry that original-indication field (see data gap below). The TxGNN model predicts it may be effective for Post-Infectious Neuralgia (i.e., postherpetic neuralgia, PHN), with 2 registered clinical trials and no dedicated publications currently supporting this specific link, and neither trial actually tests famciclovir.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not provided in this evidence pack (Data Gap DG002 — see below); herpes zoster/genital herpes is famciclovir’s well-known approved use, based on general pharmacological knowledge, not this pack’s data |
| Predicted New Indication | Post-Infectious Neuralgia |
| TxGNN Prediction Score | 99.75% |
| Evidence Level | L5 |
| South Africa Market Status | Not Marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in this evidence pack (Data Gap DG002, High severity). Based on generally established pharmacological knowledge — not sourced from this pack — famciclovir is an oral prodrug of penciclovir, a nucleoside analogue that is phosphorylated by viral thymidine kinase and inhibits herpesvirus DNA polymerase; it is widely used against varicella-zoster virus (VZV) and herpes simplex virus (HSV) infections, including herpes zoster.
Post-infectious neuralgia (essentially postherpetic neuralgia, PHN) is a well-recognized complication of herpes zoster. Early antiviral treatment during the acute zoster phase is already understood to reduce the duration and severity of zoster-associated pain, which is mechanistically adjacent to — rather than truly novel relative to — famciclovir’s existing antiviral role.
However, this mechanistic plausibility is not confirmed by the trial evidence actually retrieved: neither of the two clinical trials linked to this prediction tests famciclovir itself (see below). The prediction should therefore be read as a knowledge-graph association reflecting disease/drug-class proximity, not as direct experimental support.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT06798662 | N/A | Not Yet Recruiting | 120 | Evaluates liposomal bupivacaine and ropivacaine nerve blocks for acute herpes zoster pain, and whether nerve blockade reduces required gabapentin dosage. Does not test famciclovir. |
| NCT03120962 | N/A | Unknown | 140 | Investigates whether early oxycodone use during the acute herpes zoster phase prevents postherpetic neuralgia. Does not test famciclovir. |
Caveat: Both trials study the herpes zoster / PHN disease space but neither evaluates famciclovir as an intervention. No trial in this pack directly tests famciclovir for post-infectious neuralgia.
Literature Evidence
Currently no related literature available for this specific indication (0 PubMed records returned for “Famciclovir” + “post-infectious neuralgia” per query log).
South Africa Market Information
Famciclovir is currently not marketed in South Africa according to this evidence pack, with 0 SAHPRA registrations recorded. No product/registration data is available to tabulate.
Safety Considerations
Detailed SAHPRA-approved warnings, contraindications, and drug interaction data are not available in this evidence pack. This is flagged as Data Gap DG001 (Blocking severity) — its stated impact is that safety cannot proceed to the initial S1 safety evaluation stage. Please refer to the SAHPRA-approved Professional Information (PI), once identified, for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale:
- Safety data is a Blocking-severity gap (DG001) that by definition prevents initial safety evaluation, and no clinical trial in this pack directly tests famciclovir for the predicted indication — evidence level is L5 (model prediction only). The drug also has no current SAHPRA registration in South Africa.
To proceed, the following is needed:
- TFDA/SAHPRA-approved Professional Information (warnings, contraindications, DDI) to resolve DG001
- Confirmed mechanism-of-action documentation (DrugBank or equivalent) to resolve DG002
- Direct clinical evidence evaluating famciclovir specifically for post-infectious/postherpetic neuralgia as an endpoint (not proxy analgesic trials)
- Confirmation of famciclovir’s registration pathway/status if market entry to South Africa is being considered
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.